Product Information
AUVI-Q 0.3 MG AUTO-INJECTOR is a brand product labeled by kaleo, Inc, priced at $309.3757 per EA under NDC 60842002302. Its NADAC has been published 108 times since Sep 11, 2024.
FDA first approved this application on Aug 10, 2012. Its Orange Book therapeutic-equivalence code is BX.
Strength
.3 mg/.3mL
Manufacturer
kaleo, IncNDC
60842002302
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR
Effective Date
7/1/2026
Active Ingredients
EPINEPHRINEApproval Type
New Drug (NDA)
FDA Application
NDA201739FDA Approved
8/10/2012
TE Code
BX
On Market Since
11/15/2012
Pharmacological Classes
Price Statistics
The NADAC for AUVI-Q 0.3 MG AUTO-INJECTOR has been published 108 times since Sep 11, 2024, and over the history we have for it it has risen 3.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $309.3757 per EA |
|---|---|
| All-time high | $309.3757 (Sep 30, 2026) |
| All-time low | $297.4131 (Dec 17, 2025) |
| 52-week high | $309.3757 |
| 52-week low | $297.4131 |
| Median price | $298.0317 |
| Average price | $299.2569 |
| Largest weekly change | +4.0% (Jul 8, 2026) |
| Weeks tracked | 108 |
| Tracking since | Sep 11, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 64% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
kaleo, Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
epinephrine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Catecholamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AUVI-Q 0.3 MG AUTO-INJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for AUVI-Q 0.3 MG AUTO-INJECTOR, manufactured by kaleo, Inc, is $309.3757 per EA (NDC 60842002302), effective Sep 30, 2026.
How has the price of AUVI-Q 0.3 MG AUTO-INJECTOR changed over time?
Over the history we have for it, the NADAC for AUVI-Q 0.3 MG AUTO-INJECTOR has risen 3.7%. It has been tracked across 108 weekly CMS publications since Sep 11, 2024.
What are the highest and lowest recorded NADAC prices for AUVI-Q 0.3 MG AUTO-INJECTOR?
Since Sep 11, 2024, the NADAC for AUVI-Q 0.3 MG AUTO-INJECTOR has ranged from a low of $297.4131 (Dec 17, 2025) to a high of $309.3757 (Sep 30, 2026), with a median of $298.0317 per EA.
Are there cheaper alternatives to AUVI-Q 0.3 MG AUTO-INJECTOR?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EPINEPHRINE 0.3 MG AUTO-INJECT, is $111.9976 per EA — about 64% below AUVI-Q 0.3 MG AUTO-INJECTOR.
Who manufactures AUVI-Q 0.3 MG AUTO-INJECTOR?
AUVI-Q 0.3 MG AUTO-INJECTOR (NDC 60842002302) is labeled by kaleo, Inc, and CMS classifies it as a brand product.